Seelos Therapeutics

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system disorders. The firm's portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior in Major Depressive Disorder or Post-Traumatic Stress Disorder, amyotrophic lateral sclerosis, Sanfilippo syndrome, Parkinson's disease, other psychiatric and movement disorders plus orphan diseases. The company was founded by Raj Mehra in 1987 and is headquartered in New York, NY.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of products that address significant unmet needs in Central Nervous System (CNS) disorders and other rare disorders. The company was founded by Raj Mehra in 1987 and is headquartered in New York, NY.

NEW YORK, Dec. 21, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that it has granted a stock option to purchase 75,000 shares of common stock to one new employee. The stock option was granted pursuant to the Seelos Therapeutics, Inc. 2019 Inducement Plan and granted as an inducement material to the new employee entering into employment with Seelos in accordance with Nasdaq Listing Rule 5635(c)(4).

Seelos Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK, Dec. 16, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the 11th Annual LifeSci Partners Corporate Access Event, January 5-7 th, 2022. Raj Mehra, Ph.D.

Seelos Therapeutics to Participate in the 11th Annual LifeSci Partners Corporate Access Event

The stock price of Seelos Therapeutics Inc (NASDAQ: SEEL) fell by 6.47% today. This is why it happened.

Seelos Therapeutics Stock (SEEL): Why The Price Fell Today

NEW YORK, Dec. 6, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that it has received an issued patent from the Japanese Patent Office (Japanese patent number 6968839, titled: STRUCTURE-BASED PEPTIDE INHIBITORS OF ALPHA-SYNUCLEIN AGGREGATION), covering the composition of matter for SLS-007, a potentially disease-modifying gene therapy focused on intracellular alpha-synuclein (α-synuclein) aggregation in Parkinson's disease (PD). Seelos is currently conducting in vivo pre-clinical studies delivering SLS-007 via an adeno-associated virus (AAV) that is designed to target the non-amyloid component core (NACore) of α-synuclein to inhibit abnormal aggregation and accumulation of the α-synuclein protein in the brains of patients with Parkinson's Disease (PD).

Seelos Therapeutics Announces Issuance of Composition of Matter Patent in Japan for SLS-007

Atai Life Sciences BV

COMPASS Pathways

Cybin

Ameri Holdings

Field Trip Health Ltd

GH Research PLC

Jaguar Health

Mind Medicine MindMed

The usage of psychedelics like psilocybin, LSD, ketamine, and others are becoming more mainstream, especially with the initial steps to legalization getting moving across a number of states in the U.S. As a result, the psychedelics market is projected to grow 12.4% annually, reaching $10.75 billion in 2027.

9 Psychedelic Stocks to Watch For 2022

iX Biopharma will receive an initial US$9 million upfront payment Eligible for up to US$239 million in development and sales milestone payments Double digit royalties on future product sales of any licensed product SINGAPORE, Nov. 29, 2021 /PRNewswire/ -- iX Biopharma Ltd (SGX:42C), a specialty pharmaceutical company that develops innovative therapies using its proprietary sublingual drug delivery technology, WaferiX, announced today that it has, through its subsidiary, entered into an exclusive license agreement with Seelos Therapeutics, Inc ("Seelos") (Nasdaq: SEEL), a company focused on developing novel therapeutics for central nervous systems disorders. Under the agreement, iX Biopharma will license to Seelos its lead drug under development, Wafermine, a sublingual racemic ketamine wafer, and other products incorporating R- and S- enantiomers of ketamine utilising the WaferiX technology (the "Licensed Products").

iX Biopharma Signs Exclusive License Agreement For Wafermine And Other Sublingual Ketamine Wafer Products

NEW YORK, Nov. 24, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced it has entered into an exclusive license agreement (License Agreement), whereby it acquired a worldwide license (excluding China, Taiwan, Macau and Hong Kong) from iX Biopharma Ltd (iX Biopharma) for Wafermine™, a sublingual racemic ketamine wafer, and a worldwide license for other sublingual ketamine wafers, delivered using a proprietary fast-dissolving wafer-based drug delivery platform technology known as WaferiX™. Seelos plans to evaluate sublingual ketamine, now named SLS-003, in pain indications such as chronic neuropathic pain and Complex Regional Pain Syndrome (CRPS) and in additional psychiatric disorders, including post-traumatic stress disorder (PTSD).

Seelos Therapeutics Announces Acquisition of an Exclusive License of iX Biopharma's Proprietary Wafer-Based Delivery Platform for Sublingual Ketamine

NEW YORK, Nov. 24, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced the placement of a $22.0 million senior secured convertible note (the "Note") and shares of Seelos common stock (the "Closing Shares") to Lind Global Asset Management V, LLC, managed by The Lind Partners, a New York institutional fund manager and an existing investor in Seelos. Seelos will receive $20.0 million in gross proceeds.

Seelos Therapeutics Raises $20 Million in Private Placement of Senior Secured Convertible Note

NEW YORK, Nov. 10, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it has been selected to present at the 4th Annual ALS ONE Research Symposium, November 29-30 th, 2021. Raj Mehra, Ph.D.

Seelos Therapeutics to Present at the 4th Annual ALS ONE Research Symposium

The FDA has accepted Seelos Therapeutics Inc's (NASDAQ: SEEL) Investigation New Drug application to study SLS-005 (trehalose injection, 90.5 mg/mL) for spinocerebellar Ataxia (SCA).  The FDA has also granted the program Fast Track designation for SCA, and SLS-005 has previously received Orphan Drug designation for spinocerebellar ataxia type 3 (SCA3) from the FDA and the European Medicines Agency.

Seelos Therapeutics To Test Trehalose In Patients With Rare Movement Control Disorder

NEW YORK, Nov. 8, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that the U.S. Food and Drug Administration (FDA) has accepted Seelos' Investigation New Drug (IND) application to study SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion) for the treatment of spinocerebellar ataxia (SCA). The FDA has also granted the program Fast Track designation in the U.S. for SCA, and SLS-005 has previously received Orphan Drug designation for spinocerebellar ataxia type 3 (SCA3) from the FDA and from the European Medicines Agency in the EU.

Seelos Therapeutics Announces FDA Acceptance of Investigational New Drug Application and Grant of Fast Track Designation for SLS-005 (IV Trehalose) for the Treatment of Spinocerebellar Ataxia

NEW YORK, Nov. 2, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the Guggenheim Healthcare Talks, Idea Forum, 3rd Annual Neuro/Immunology Day on November 15-16 th and in The Benchmark Company 10th Annual Discovery One on One Investor Conference on December 2 nd, 2021. Guggenheim Healthcare Talks, Idea Forum, 3rd Annual Neuro/Immunology Day Raj Mehra, Ph.D.

Seelos Therapeutics to Participate in Two Investor Conferences

Ambev

Seanergy Maritime Hlds

Which trending penny stocks are you watching next month? The post Are These Trending Penny Stocks on Your Watchlist Right Now?

Are These Trending Penny Stocks on Your Watchlist Right Now?

Biotricity

Progenity

Why investors are watching these biotech penny stocks right now The post 3 Biotech Penny Stocks to Watch That Are Climbing Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Biotech Penny Stocks to Watch That Are Climbing Right Now

Cinedigm

NanoVibronix

Are these penny stocks on your October watchlist? The post Top Penny Stocks to Know in Mid-October 2021?

Top Penny Stocks to Know in Mid-October 2021? 3 to Watch

Senseonics Holdings

Are these Reddit penny stocks on your small-caps watchlist right now? The post Hot Penny Stocks That Investors on Reddit Are Watching Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks That Investors on Reddit Are Watching Right Now

Vinco Ventures

Centennial Resource Development

With October only a few days away, here are three penny stocks you might want to take a look at The post Best Penny Stocks to Buy? Check 3 These Out Next Month appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Buy? Check 3 These Out Next Month

Part A results from the trial of Seelos Therapeutics Inc's (NASDAQ:SEEL) intranasal ketamine product candidate, SLS-002, and the clarity around the timing of the Part B data release call for a change in recommendation, according to Roth Capital. The Seelos Therapeutics Analyst: Jonathan Aschoff upgraded the rating for Seelos Therapeutics from Neutral to Buy and raised the price target from $2.50 to $8.

Why This Seelos Therapeutics Analyst Is Turning Bullish On Potential Trial Results

Investors need to pay close attention to Seelos (SEEL) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Seelos (SEEL) Stock?

Atossa Genetics

Genius Brands

Reddit penny stocks are here to stay; have you heard of these three? The post Hot Penny Stocks on Reddit to Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks on Reddit to Watch Right Now

The Sean M. Healey & AMG Center for ALS at Mass General received approval from the FDA and the Mass General Brigham Institutional Review Board to add SLS-005 (trehalose injection, 90.5 mg/ML for intravenous infusion) as an additional regimen in the HEALEY ALS Platform Trial.

Seelos Therapeutics Shares Gain On FDA Approval To Add SLS-005 Regimen In HEALEY ALS Trial

NEW YORK, Sept. 9, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the M-Vest Advances in Mental Health, Psychedelic and Non-Psychedelic Virtual Conference on September 22 nd and the Cantor Virtual Global Healthcare Conference, September 27 th-30th, 2021.

Seelos Therapeutics to Participate in Two Investor Conferences in September

NEW YORK, Sept. 2, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today the appointment of Margaret Dalesandro, Ph.D.

Seelos Therapeutics Announces Appointment of Margaret Dalesandro to the Board of Directors

NEW YORK, Sept. 1, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced the promotions of Michael Golembiewski to Chief Financial Officer and Anthony Marciano to Chief Communications Officer, each effective September 1, 2021.

Seelos Therapeutics Announces Senior Management Appointments

NEW YORK, Aug. 9, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced its mid-year 2021 business and clinical update. "In the first half of 2021, the Seelos team continued to execute at a very high level.

News for Seelos Therapeutics Stock (SEEL)